1.Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
Jun Sung MOON ; Sunghwan SUH ; Sang Soo KIM ; Heung Yong JIN ; Jeong Mi KIM ; Min Hee JANG ; Kyung Ae LEE ; Ju Hyung LEE ; Seung Min CHUNG ; Young Sang LYU ; Jin Hwa KIM ; Sang Yong KIM ; Jung Eun JANG ; Tae Nyun KIM ; Sung Woo KIM ; Eonju JEON ; Nan Hee CHO ; Mi-Kyung KIM ; Hye Soon KIM ; Il Seong NAM-GOONG ; Eun Sook KIM ; Jin Ook CHUNG ; Dong-Hyeok CHO ; Chang Won LEE ; Young Il KIM ; Dong Jin CHUNG ; Kyu Chang WON ; In Joo KIM ; Tae Sun PARK ; Duk Kyu KIM ; Hosang SHON
Diabetes & Metabolism Journal 2021;45(5):675-683
		                        		
		                        			
		                        			 Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM). From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated. In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9±14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, −1.1%±1.2%;  This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy.
		                        		
		                        	
2.Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
Jun Sung MOON ; Sunghwan SUH ; Sang Soo KIM ; Heung Yong JIN ; Jeong Mi KIM ; Min Hee JANG ; Kyung Ae LEE ; Ju Hyung LEE ; Seung Min CHUNG ; Young Sang LYU ; Jin Hwa KIM ; Sang Yong KIM ; Jung Eun JANG ; Tae Nyun KIM ; Sung Woo KIM ; Eonju JEON ; Nan Hee CHO ; Mi-Kyung KIM ; Hye Soon KIM ; Il Seong NAM-GOONG ; Eun Sook KIM ; Jin Ook CHUNG ; Dong-Hyeok CHO ; Chang Won LEE ; Young Il KIM ; Dong Jin CHUNG ; Kyu Chang WON ; In Joo KIM ; Tae Sun PARK ; Duk Kyu KIM ; Hosang SHON
Diabetes & Metabolism Journal 2021;45(5):675-683
		                        		
		                        			
		                        			 Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM). From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated. In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9±14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, −1.1%±1.2%;  This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy.
		                        		
		                        	
3.Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
Jun Sung MOON ; Sunghwan SUH ; Sang Soo KIM ; Heung Yong JIN ; Jeong Mi KIM ; Min Hee JANG ; Kyung Ae LEE ; Ju Hyung LEE ; Seung Min CHUNG ; Young Sang LYU ; Jin Hwa KIM ; Sang Yong KIM ; Jung Eun JANG ; Tae Nyun KIM ; Sung Woo KIM ; Eonju JEON ; Nan Hee CHO ; Mi-Kyung KIM ; Hye Soon KIM ; Il Seong NAM-GOONG ; Eun Sook KIM ; Jin Ook CHUNG ; Dong-Hyeok CHO ; Chang Won LEE ; Young Il KIM ; Dong Jin CHUNG ; Kyu Chang WON ; In Joo KIM ; Tae Sun PARK ; Duk Kyu KIM ; Hosang SHON
Diabetes & Metabolism Journal 2020;44(S1):e46-
		                        		
		                        			 Background:
		                        			Only few studies have shown the efficacy and safety of glucose-control strategies using the quadruple drug combination. Therefore, the aim of the present study was to investigate the usefulness of the quadruple combination therapy with oral hypoglycemic agents (OHAs) in patients with uncontrolled type 2 diabetes mellitus (T2DM). 
		                        		
		                        			Methods:
		                        			From March 2014 to December 2018, data of patients with T2DM, who were treated with quadruple hypoglycemic medications for over 12 months in 11 hospitals in South Korea, were reviewed retrospectively. We compared glycosylated hemoglobin (HbA1c) levels before and 12 months after quadruple treatment with OHAs. The safety, maintenance rate, and therapeutic patterns after failure of the quadruple therapy were also evaluated. 
		                        		
		                        			Results:
		                        			In total, 357 patients were enrolled for quadruple OHA therapy, and the baseline HbA1c level was 9.0%±1.3% (74.9± 14.1 mmol/mol). After 12 months, 270 patients (75.6%) adhered to the quadruple therapy and HbA1c was significantly reduced from 8.9%±1.2% to 7.8%±1.3% (mean change, –1.1%±1.2%; P<0.001). The number of patients with HbA1c <7% increased significantly from 5 to 68 (P<0.005). In addition, lipid profiles and liver enzyme levels were also improved whereas no changes in body weight. There was no significant safety issue in patients treated with quadruple OHA therapy. 
		                        		
		                        			Conclusion
		                        			This study shows the therapeutic efficacy of the quadruple OHA regimen T2DM and demonstrates that it can be an option for the management of T2DM patients who cannot use insulin or reject injectable therapy. 
		                        		
		                        		
		                        		
		                        	
4.Gray Matter Microstructural Abnormalities and Working Memory Deficits in Individuals with Schizophrenia
HyunJung KIM ; Seung Hyun SHON ; Sung Woo JOO ; Woon YOON ; Jang Han LEE ; Ji Won HUR ; JungSun LEE
Psychiatry Investigation 2019;16(3):234-243
		                        		
		                        			
		                        			OBJECTIVE: Working memory impairments serve as prognostic factors for patients with schizophrenia. Working memory deficits are mainly associated with gray matter (GM) thickness and volume. We investigated the association between GM diffusivity and working memory in controls and individuals with schizophrenia. METHODS: T1 and diffusion tensor images of the brain, working memory task (letter number sequencing) scores, and the demographic data of 90 individuals with schizophrenia and 97 controls were collected from the SchizConnect database. T1 images were parcellated into the 68 GM Regions of Interest (ROI). Axial Diffusivity (AD), Fractional Anisotropy (FA), Radial Diffusivity (RD), and Trace (TR) were calculated for each of the ROIs. RESULTS: Compared to the controls, schizophrenia group showed significantly increased AD, RD, and TR in specific regions on the frontal, temporal, and anterior cingulate area. Moreover, working memory was negatively correlated with AD, RD, and TR in the lateral orbitofrontal, superior temporal, inferior temporal, and rostral anterior cingulate area on left hemisphere in the individuals with schizophrenia. CONCLUSION: These results demonstrated GM microstructural abnormalities in the frontal, temporal, and anterior cingulate regions of individuals with schizophrenia. Furthermore, these regional GM microstructural abnormalities suggest a neuropathological basis for the working memory deficits observed clinically in individuals with schizophrenia.
		                        		
		                        		
		                        		
		                        			Anisotropy
		                        			;
		                        		
		                        			Brain
		                        			;
		                        		
		                        			Diffusion
		                        			;
		                        		
		                        			Diffusion Tensor Imaging
		                        			;
		                        		
		                        			Gray Matter
		                        			;
		                        		
		                        			Gyrus Cinguli
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Memory, Short-Term
		                        			;
		                        		
		                        			Schizophrenia
		                        			
		                        		
		                        	
5.Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma
Ho Won KANG ; Hongyong PARK ; Sung Pil SEO ; Young Joon BYUN ; Xuan Mei PIAO ; Sung Min KIM ; Won Tae KIM ; Seok Joong YUN ; Wooyeong JANG ; Ho Sun SHON ; Keun Ho RYU ; Sang Cheol LEE ; Wun Jae KIM ; Yong June KIM
Journal of Korean Medical Science 2019;34(19):e144-
		                        		
		                        			
		                        			BACKGROUND: Little is known about epigenetic silencing of genes by promoter hypermethylation in renal cell carcinoma (RCC). The aim of this study was to identify prognostic methylation markers in surgically treated clear cell RCC (ccRCC). METHODS: Methylation patterns were assayed using the Infinium HumanMethylation450 BeadChip array on pairs of ccRCC and normal tissue from 12 patients. Using quantitative PSQ analysis, tumor-specific hypermethylated genes were validated in 25 independent cohorts and their clinical relevance was also verified in 152 independent cohorts. RESULTS: Using genome-wide methylation array, Zinc finger protein 278 (ZNF278), Family with sequence similarity 155 member A (FAM155A) and Dipeptidyl peptidase 6 (DPP6) were selected for tumor-specific hypermethylated genes in primary ccRCC. The promoter methylation of these genes occurred more frequently in ccRCC than normal kidney in independent validation cohort. The hypermethylation of three genes were associated with advanced tumor stage and high grade tumor in ccRCC. During median follow-up of 39.2 (interquartile range, 15.4–79.1) months, 22 (14.5%) patients experienced distant metastasis. Multivariate analysis identified the methylation status of these three genes, either alone, or in a combined risk score as an independent predictor of distant metastasis. CONCLUSION: The promoter methylation of ZNF278, FAM155A and DPP6 genes are associated with aggressive tumor phenotype and early development of distant metastasis in patients with surgically treated ccRCC. These potential methylation markers, either alone, or in combination, could provide novel targets for development of individualized therapeutic and prevention regimens.
		                        		
		                        		
		                        		
		                        			Carcinoma, Renal Cell
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Epigenomics
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Methylation
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Phenotype
		                        			;
		                        		
		                        			Zinc Fingers
		                        			
		                        		
		                        	
6.Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome following HAART Initiation in an HIV-infected Patient Being Treated for Severe Pneumocystis jirovecii Pneumonia: Case Report and Literature Review.
Dong Won PARK ; Dae Hyun LIM ; Bongyoung KIM ; Ji Young YHI ; Ji Yong MOON ; Sang Heon KIM ; Tae Hyung KIM ; Jang Won SHON ; Ho Joo YOON ; Dong Ho SHIN ; Hyunjoo PAI
Korean Journal of Critical Care Medicine 2016;31(2):162-168
		                        		
		                        			
		                        			Pnuemocystis jirovecii pneumonia (PJP) is one of leading causes of acute respiratory failure in patients infected with human immunodeficiency virus (HIV), and the mortality rate remains high in mechanically ventilated HIV patients with PJP. There are several reported cases who received extracorporeal membrane oxygenation (ECMO) treatment for respiratory failure associated with severe PJP in HIV-infected patients. We report a patient who was newly diagnosed with HIV and PJP whose condition worsened after highly active antiretroviral therapy (HAART) initiation and progressed to acute respiratory distress syndrome requiring veno-venous ECMO. The patient recovered from PJP and is undergoing treatment with HAART. ECMO support can be an effective life-saving salvage therapy for acute respiratory failure refractory to mechanical ventilation following HAART in HIV-infected patients with severe PJP.
		                        		
		                        		
		                        		
		                        			Antiretroviral Therapy, Highly Active*
		                        			;
		                        		
		                        			Extracorporeal Membrane Oxygenation*
		                        			;
		                        		
		                        			HIV
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Pneumocystis jirovecii*
		                        			;
		                        		
		                        			Pneumocystis*
		                        			;
		                        		
		                        			Pneumonia*
		                        			;
		                        		
		                        			Respiration, Artificial
		                        			;
		                        		
		                        			Respiratory Distress Syndrome, Adult*
		                        			;
		                        		
		                        			Respiratory Insufficiency
		                        			;
		                        		
		                        			Salvage Therapy
		                        			
		                        		
		                        	
7.Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome following HAART Initiation in an HIV-infected Patient Being Treated for Severe Pneumocystis jirovecii Pneumonia: Case Report and Literature Review
Dong Won PARK ; Dae Hyun LIM ; Bongyoung KIM ; Ji Young YHI ; Ji Yong MOON ; Sang Heon KIM ; Tae Hyung KIM ; Jang Won SHON ; Ho Joo YOON ; Dong Ho SHIN ; Hyunjoo PAI
The Korean Journal of Critical Care Medicine 2016;31(2):162-168
		                        		
		                        			
		                        			Pnuemocystis jirovecii pneumonia (PJP) is one of leading causes of acute respiratory failure in patients infected with human immunodeficiency virus (HIV), and the mortality rate remains high in mechanically ventilated HIV patients with PJP. There are several reported cases who received extracorporeal membrane oxygenation (ECMO) treatment for respiratory failure associated with severe PJP in HIV-infected patients. We report a patient who was newly diagnosed with HIV and PJP whose condition worsened after highly active antiretroviral therapy (HAART) initiation and progressed to acute respiratory distress syndrome requiring veno-venous ECMO. The patient recovered from PJP and is undergoing treatment with HAART. ECMO support can be an effective life-saving salvage therapy for acute respiratory failure refractory to mechanical ventilation following HAART in HIV-infected patients with severe PJP.
		                        		
		                        		
		                        		
		                        			Antiretroviral Therapy, Highly Active
		                        			;
		                        		
		                        			Extracorporeal Membrane Oxygenation
		                        			;
		                        		
		                        			HIV
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Pneumocystis jirovecii
		                        			;
		                        		
		                        			Pneumocystis
		                        			;
		                        		
		                        			Pneumonia
		                        			;
		                        		
		                        			Respiration, Artificial
		                        			;
		                        		
		                        			Respiratory Distress Syndrome, Adult
		                        			;
		                        		
		                        			Respiratory Insufficiency
		                        			;
		                        		
		                        			Salvage Therapy
		                        			
		                        		
		                        	
8.The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production.
Jiyea CHOI ; Hyemin KIM ; Yejin KIM ; Mirim JANG ; Jane JEON ; Young Il HWANG ; Won Jun SHON ; Yeong Wook SONG ; Jae Seung KANG ; Wang Jae LEE
Immune Network 2015;15(6):291-303
		                        		
		                        			
		                        			GV1001 is a peptide derived from the human telomerase reverse transcriptase (hTERT) sequence that is reported to have anti-cancer and anti-inflammatory effects. Enolase1 (ENO1) is a glycolytic enzyme, and stimulation of this enzyme induces high levels of pro-inflammatory cytokines from concanavalin A (Con A)-activated peripheral blood mononuclear cells (PBMCs) and ENO1-expressing monocytes in healthy subjects, as well as from macrophages in rheumatoid arthritis (RA) patients. Therefore, this study investigated whether GV1001 downregulates ENO1-induced pro-inflammatory cytokines as an anti-inflammatory peptide. The results showed that GV1001 does not affect the expression of ENO1 in either Con A-activated PBMCs or RA PBMCs. However, ENO1 stimulation increased the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6, and these cytokines were downregulated by pretreatment with GV1001. Moreover, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB were activated when ENO1, on the surface of Con A-activated PBMCs and RA PBMCs, was stimulated, and they were successfully suppressed by pre-treatment with GV1001. These results suggest that GV1001 may be an effective anti-inflammatory peptide that downregulates the production of pro-inflammatory cytokines through the suppression of p38 MAPK and NF-kappaB activation following ENO1 stimulation.
		                        		
		                        		
		                        		
		                        			Arthritis, Rheumatoid
		                        			;
		                        		
		                        			Concanavalin A
		                        			;
		                        		
		                        			Cytokines
		                        			;
		                        		
		                        			Down-Regulation*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammation
		                        			;
		                        		
		                        			Interleukin-6
		                        			;
		                        		
		                        			Interleukins
		                        			;
		                        		
		                        			Macrophages
		                        			;
		                        		
		                        			Monocytes
		                        			;
		                        		
		                        			NF-kappa B
		                        			;
		                        		
		                        			p38 Mitogen-Activated Protein Kinases
		                        			;
		                        		
		                        			Protein Kinases
		                        			;
		                        		
		                        			Telomerase
		                        			;
		                        		
		                        			Tumor Necrosis Factor-alpha
		                        			
		                        		
		                        	
9.Candida Arthritis in a Hemodialysis Patient.
Soo Yeon PARK ; Yong Hwan KWON ; Seok Won KIM ; Dong Won JANG ; Yeon Oh JUNG ; Min Soo SHON ; Ran Hui CHA
Journal of the Korean Geriatrics Society 2014;18(2):93-97
		                        		
		                        			
		                        			Candida is a rare cause of infectious arthritis, and it can be found in infants and immunocompromised patients. Patients with maintenance hemodialysis are prone to opportunistic infections because of altered immunity, and frequent exposures to health-care associated infections. Herein, we report a case of candida arthritis of right shoulder with preceding fungemia in patients with maintenance hemodialysis. The diagnosis is based on the isolation of Candida Tropicalis from blood and synovial fluids of the shoulder joint. The patient has received intravenous fluconazole and arthroscopic surgical debridement. We then changed the fluconazole into amphotericin B due to the abnormal signs in the liver function tests, although the fluconazole successfully controlled fungemia and arthritis. To the best of our knowledge, this is the first case of candida arthritis in patients with maintenance hemodialysis in South Korea.
		                        		
		                        		
		                        		
		                        			Amphotericin B
		                        			;
		                        		
		                        			Arthritis*
		                        			;
		                        		
		                        			Arthritis, Infectious
		                        			;
		                        		
		                        			Candida tropicalis
		                        			;
		                        		
		                        			Candida*
		                        			;
		                        		
		                        			Debridement
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Fluconazole
		                        			;
		                        		
		                        			Fungemia
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunocompromised Host
		                        			;
		                        		
		                        			Infant
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Liver Function Tests
		                        			;
		                        		
		                        			Opportunistic Infections
		                        			;
		                        		
		                        			Renal Dialysis*
		                        			;
		                        		
		                        			Shoulder
		                        			;
		                        		
		                        			Shoulder Joint
		                        			;
		                        		
		                        			Synovial Fluid
		                        			
		                        		
		                        	
10.Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study.
Sang Hoon PARK ; Choong Kee PARK ; Jin Woo LEE ; Young Seok KIM ; Sook Hyang JEONG ; Yun Soo KIM ; Ju Hyun KIM ; Seong Gyu HWANG ; Kyu Sung RIM ; Hyung Joon YIM ; Jae Youn CHEONG ; Sung Won CHO ; June Sung LEE ; Young Min PARK ; Jeong Won JANG ; Chun Kyon LEE ; Joo Hyun SHON ; Jin Mo YANG ; Young Soo JU
Gut and Liver 2012;6(1):98-106
		                        		
		                        			
		                        			BACKGROUND/AIMS: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. METHODS: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea. RESULTS: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was > or =6x10(5) IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6x10(5) IU/mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). CONCLUSIONS: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.
		                        		
		                        		
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Hepacivirus
		                        			;
		                        		
		                        			Hepatitis C, Chronic
		                        			;
		                        		
		                        			Hepatitis, Chronic
		                        			;
		                        		
		                        			Hospitals, University
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Medical Records
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Ribavirin
		                        			;
		                        		
		                        			RNA
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail